In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.
Those already in the cannabis industry and those looking to get into it will get a chance to learn more about newest adult-use markets in the country, how they compare to one another, and what we can anticipate as these new opportunities take shape.
This panel seeks to get to the bottom of the IFR and what it means for the hemp CBD industry currently and in the future. We may also touch on the intersection of USDA and FDA authority to regulate hemp-derived CBD products.
This panel will address current and emerging challenges surrounding such methods and new products from the business, legal, and regulatory perspectives. Topics will include the vaping crisis, regulation of novel delivery systems, hardware inputs and related supply chain matters, various approaches to the regulation of edibles, hemp, and hemp-derived CBD, and what the future may hold.
This CLE will examine equity policy considerations on both the statutory level and the regulatory level, and will inform attorneys and non-attorneys alike what to look for when reading, drafting or recommending policy language, how to engage policy makers and shed light on equity successes, failures and pitfalls to avoid.
Niall will discuss cannabis jurisdiction, legislation, regulation, Medical Cannabis Access Programme (MCAP, the Specified Controlled Drugs (Cannabis-Based Medical Products), indications, CBD - Novel Foods (Conflict of Laws), and adult use in the Republic of Ireland.